Spero Therapeutics Appoints William Ho to Board
The biopharmaceutical company added Dr. William Ho to its Board of Directors and Development Committee, filling the seat vacated by Patrick Vink.
Updated on Nov. 10, 2026 in People

Spero Therapeutics appointed William Ho, M.D., Ph.D., to its Board of Directors and Development Committee, effective November 10, 2026. Dr. Ho fills the vacancy left by Patrick Vink, who stepped down after an eleven-year tenure on the Board.
Why it matters
The appointment adds a clinical development leader with immunology experience to Spero's board as the company advances SP001 and evaluates expanding its pipeline of therapies for immune-mediated diseases. Board composition changes like this one can shape oversight of a company's long-term strategy.
Dr. Vink's eleven-year Board tenure ended as Dr. Ho, who served as RAPT Therapeutics' Chief Medical Officer from 2015 to December 2025, joins the Board. RAPT was acquired by GSK for $2.2 billion, finalized in March 2026, but the announcement does not disclose Spero's own financial terms for the appointment.
The players
Spero Therapeutics
Spero Therapeutics is a Cambridge, Massachusetts-based biopharmaceutical company developing therapies for immune-mediated diseases, including its lead candidate SP001.
William Ho, M.D., Ph.D.
Dr. Ho is a physician-scientist with more than 20 years of clinical development experience, who previously held senior roles at Genentech and RAPT Therapeutics.
The details
Spero Therapeutics, based in Cambridge, Mass., announced that Dr. Ho will join the Board and its Development Committee, effective November 10, 2026, filling the seat left by Dr. Vink's departure. Dr. Ho previously led U.S. and ex-China development strategy for an in-licensed anti-IgE monoclonal antibody at RAPT Therapeutics.
Timeline
November 10, 2026: Dr. Ho's Board and Development Committee appointment takes effect.
2015 to December 2025: Dr. Ho served as Chief Medical Officer of RAPT Therapeutics.
March 2026: GSK's $2.2 billion acquisition of RAPT Therapeutics was finalized.
Industry Context
Dr. Ho's move follows GSK's $2.2 billion acquisition of RAPT Therapeutics, finalized in March 2026, which ended RAPT's run as an independent company. Experienced clinical leaders from acquired biotechs increasingly carry their expertise into smaller independent firms, as Dr. Ho is doing with Spero.
For shareholders, the appointment changes who sits on the Board overseeing Spero's pipeline decisions, including the planned SP001 advancement. Patients and investors in immune-mediated disease therapies may see the company's strategy shaped by an experienced development leader.
The takeaway
Board appointments often signal where a company's priorities lie. Spero's choice of a clinical development leader suggests a focus on advancing its immunology pipeline.
Further reading
Explore more business people news from across the region.
More information
Learn more on the Spero Therapeutics company website.
Source note: This article includes information reported by The Manila times.






